In a study of 34 patients with PDA (18/34 and 16/34 received G-NP and FOLFIRINOX, respectively; 26 had chemo-radiation, 22 with capecitabine, and 4 with Gem), 71% of patients who underwent resection showed a statically significant decrease in levels of mut-KRAS cfDNA compared with pre-treatment. This evidence concerns the gene KRAS and Patent ductus arteriosus.